Enters into a Cooperation Agreement CALGARY, Alberta, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it has entered into a cooperation agreement with the Supreme Council of the Arab-African Economy which has expressed an interest in providing necessary investments and partnerships to support the entry of Resverlogix’s first-in-class drug – apabetalone into the Arab-African Economy.
“We are excited to be collaborating with the Supreme Council of the Arab-African Economy under the leadership of His Excellency Dr. Hani Abu Zaid,” said Donald J. McCaffrey, President & CEO of Resverlogix. “By entering into this cooperation agreement, it will assist our approach in strengthening our relationships, developments, and interests within the Arab-African Economy, while propelling the development of apabetalone,” further commented Mr. McCaffrey.
“The Supreme Council of the Arab-African Economy is pleased to be in collaboration with Resverlogix to provide the necessary investment and assistance to support the emergence of apabetalone into the Arab-African Economy. We look forward to working with Mr. McCaffrey and his team of world-class scientists and experts in the field of epigenetics,” stated His Excellency Dr. Hani Abu Zaid, President of the Supreme Council for the Arab-African Economy.
Resverlogix has been actively working with hospitals and the respective ministries globally to commence COVID-19 clinical trials. On October 12th, 2021 Resverlogix received ethics committee approval for Western Canadian sites in a Phase 2 clinical trial for apabetalone in COVID-19 patients. On November 1st, 2021 the Canadian arm of the trial began actively recruiting patients. Additionally, a Phase 3 COVID-19 trial in the US is anticipated to commence in coming months based on final protocol approval.
Phase 2 Trial Overview – Canada/Brazil
Study participants will be made up of patients hospitalized with confirmed COVID-19 cases. Participants will either receive twice daily doses of apabetalone for up to 4 weeks alongside standard of care, compared to standard of care alone. The primary outcome measure of the study will be change in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. A total of 100 patients are expected to be enrolled at multiple sites in Canada and Brazil. The study is actively recruiting in the Canadian arm. The full study protocol can be found on clinicaltrials.gov.
About the Supreme Council of Arab-African Economy - The Council’s Mandate
The Supreme Economic Council for the Arab-African Economy is an economic-diplomatic body recognized by the United Nations, European Union, Arab League, and the Common Market for Eastern and Southern Africa (COMESA). The Supreme Economic Council for the Arab-African Economy specializes in promoting and facilitating investments and trade in member nations and affiliates to strengthen their economies.
https://www.globenewswire.com/en/news-release/2021/11/03/2326341/0/en/Resverlogix-Enters-into-a-Cooperation-Agreement-with-the-Supreme-Council-of-the-Arab-African-Economy-to-Support-the-Development-of-Apabetalone-for-COVID-19-Patients.html